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TRIL, a Functional Component of the TLR4 Signaling
Complex, Highly Expressed in Brain1
Susan Carpenter,*‡ Thaddeus Carlson,§ Jerome Dellacasagrande,‡ Amaya Garcia,‡¶
Sharon Gibbons,‡ Paul Hertzog, Anthony Lyons,† Lih-Ling Lin,§ Marina Lynch,†
Tom Monie,# Caroline Murphy,*‡ Katherine J. Seidl,§ Christine Wells,** Aisling Dunne,2*
and Luke A. J. O’Neill2,3*
TLR4 is the primary sensor of LPS. In this study, we describe for the first time TLR4 interactor with leucine-rich repeats (TRIL),
which is a novel component of the TLR4 complex. TRIL is expressed in a number of tissues, most prominently in the brain but
also in the spinal cord, lung, kidney, and ovary. TRIL is composed of a signal sequence, 13 leucine-rich repeats, a fibronectin
domain, and a single transmembrane spanning region. TRIL is induced by LPS in the human astrocytoma cell line U373, in
murine brain following i.p. injection, and in human PBMC. Endogenous TRIL interacts with TLR4 and this interaction is greatly
enhanced following LPS stimulation. TRIL also interacts with the TLR4 ligand LPS. Furthermore, U373 cells stably overex-
pressing TRIL display enhanced cytokine production in response to LPS. Finally, knockdown of TRIL using small interfering
RNA attenuates LPS signaling and cytokine production in cell lines, human PBMC, and primary murine mixed glial cells. These
results demonstrate that TRIL is a novel component of the TLR4 complex which may have particular relevance for the functional
role of TLR4 in the brain. The Journal of Immunology, 2009, 183: 3989–3995.
T oll-like receptors are germline-encoded type 1 transmem-brane receptors involved in the innate recognition of mi-crobial products (1). TLRs possess large leucine-rich re-
peats (LRRs)4 within their extracellular domain that serve to
function in ligand recognition. The cytoplasmic region of the TLRs
is made up of a Toll/IL-1R homology domain, which is involved
in the downstream signaling cascades initiated following receptor
engagement (2). Localization of TLRs is essential to their function.
TLRs 1, 2, 4, 5, and 6 are localized to the cell surface where they
directly sense microbial products such as LPS in the case of TLR4
and lipopeptides in the case of TLR2. TLRs 3, 7, 8, and 9 are all
localized to endosomal compartments where they are responsible
for the recognition of microbial and possibly host-derived nucleic
acids.
Accessory molecules are required for signal activation by a
number of TLRs. Some accessory molecules are involved in reg-
ulating the cell surface expression of TLRs while others are in-
volved in ligand delivery and binding. A number of accessory
molecules have been implicated in the TLR4 signaling pathway.
MD2, for example, binds LPS and acts as the endotoxin recogni-
tion molecule allowing TLR4 to signal (3). MD2 is indispensable
for TLR4 signaling since MD2-deficient mice are unresponsive to
LPS (3, 4). CD14 is a LRR-containing glycoprotein that can be
secreted into the serum or expressed as a GPI-linked protein on the
surface of cells (5). The function of CD14 is to bind LPS and
transfer LPS monomers to TLR4/MD2 (6). PRAT4A was origi-
nally identified as a TLR4-specific chaperone protein (7); however,
it now appears that PRAT4A also plays a role in TLR1 and TLR9
signaling (8). Gp96, an endoplasmic reticulum chaperone protein,
was recently shown to be required not only for TLR4 signaling but
also for TLR3, TLR5, TLR7, and TLR9 signaling. Gp96 appears
to be required for posttranslational maturation of TLR proteins (9,
10). Some accessory molecules play roles that are cell-type spe-
cific, such as RP105, which is required for TLR2- and TLR4-
mediated responses in B cells (3). In macrophages and dendritic
cells however, RP105 acts as a negative regulator of TLR4 sig-
naling (11).
Accessory molecules are clearly vital components of TLR sig-
naling complexes. In this study, we describe a previously uniden-
tified and highly conserved novel protein, TRIL (TLR4 interactor
with leucine-rich repeats; GenBank accession no. NM_014817),
which plays an important and functional role in the TLR4 com-
plex. It contains 13 LRRs, a signal sequence, a fibronectin domain,
and a single transmembrane spanning region. The LRR motifs are
similar to those found in other LRR proteins such as TLRs,
NOGO, and LINGO receptors. TRIL is highly expressed in a num-
ber of tissues, notably in brain, and is up-regulated by LPS both in
vitro and in vivo. We show that TRIL can interact with TLR4 and
this interaction is greatly enhanced upon LPS stimulation. We also
demonstrate that TRIL can bind to LPS. Silencing of TRIL atten-
uates the TLR4 signaling pathway in cell lines, human PBMC, and
murine mixed glial cells. This study therefore demonstrates that
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TRIL is a functional protein in the TLR4 complex that may have
particular relevance for TLR4-mediated responses in brain.
Materials and Methods
Reagents
Anti-Flag Ab and anti-Flag-agarose were purchased from Sigma-Aldrich.
Anti--actin Ab was purchased from Sigma-Aldrich. The IB- Ab was a
gift from Prof. R. Hay (University of Dundee, Dundee, U.K.). The poly-
clonal phospho-p38 Ab was obtained from Cell Signaling Technology. The
anti-TLR4 Ab was purchased from Imgenex. The anti-mouse IgG (whole
molecule) peroxidase conjugate and anti-rabbit IgG (whole molecule) per-
oxidase conjugate Abs were all purchased from Jackson ImmunoResearch
Laboratories. LPS (TLR4 grade) from Escherichia coli serotype EH100
was obtained from Alexis. rTNF- as well as IL-6, IL-8, IL-1, TNF-,
and RANTES ELISAs were obtained from R&D Systems. Human and
murine cDNA panels were obtained from BD Clontech. Human protein
tissue samples were obtained from BD Clontech. The human macro-
phage THP1 cell line, HEK293 cells, and U373 parental cells were
obtained from the European Collection of Animal Cell Cultures. U373/
CD14 cells were a gift from Prof. Doug Golenboch (University of Mas-
sachusetts, Boston, MA).
Homology modeling studies
Predicted structural domains in TRIL were identified using the Meta Server
3D-Jury. Alignments were manually adjusted and used as templates to
generate models using Modeler 9v3 (12). The Lingo-1 ectodomain (pdb
2id5) was the template for the LRR domain.
Animals
C57BL/6 mice (3–4 mo old) were purchased from Harlan. Animals had
free access to food and water, were housed in groups of three to six in a
controlled environment (temperature: 20–22°C; 12:12-h light/dark cycle),
and were maintained under veterinary supervision for the duration of the
experiment. All experiments were conducted under a license from the De-
partment of Health and Children (Ireland) and with ethical approval from
Trinity College Ethical Committee. For LPS induction experiments,
C57BL/6 mice were injected with either saline or LPS (100 g/kg E. coli
serotype 0111.B4; Sigma-Aldrich) i.p. and 3 h later mice were killed by
cervical dislocation and the brain was rapidly removed and stored snap
frozen until required for analysis.
Ab characterization
Two rabbit polyclonal anti-TRIL Abs were raised against a peptide se-
quence in the C terminus of the protein, aa 797–811-SLRREDRLLQR
FAD (Eurogentic/21Century Biochemicals), one of which was affinity pu-
rified. Ab specificity was confirmed by peptide competition analysis.
HEK293 cells were seeded at 1  105 cells/ml into 6-well plates. Cells
were either mock transfected or transfected with 3 g of TRIL. Samples
were harvested and electrophoresed on 10% SDS gels, transferred to poly-
vinylidene fluoride membrane, and blocked in 5% (w/v) dried milk in
TBS-Tween 20 buffer. Samples were either probed directly using anti-
TRIL Ab or the primary Ab was incubated at 30oC for 30 min with 20
g/ml of its corresponding competing peptide.
Cell culture and stable cell line generation
HEK293 cells and U373 parental cells were maintained in DMEM and
THP1 cells were maintained in RPMI 1640. All medium used was sup-
plemented with 10% FCS and 1% penicillin-streptomycin solution (v/v).
Cerebellar granule neurons were isolated from the dissociated cerebella
from 5-day-old rats. Cells were gently dissociated with a Pasteur pipette
using 0.4% trypsin and 0.1% DNase I at room temperature. Cells were
maintained in DMEM/F12. Cells were also maintained in 10 M cytosine-
1--D-arabinofuranoside solution. Cells were maintained on poly-L-orni-
thine-coated plates. Cortical astrocytes were isolated from the cortex of
5-day-old rats and maintained in DMEM for 10 days before treatment.
Human PBMC were isolated from human blood and maintained in IMDM.
Primary murine mixed glia cells were obtained from 1-day-old neonatal
brains. Cells were cultured in DMEM for 10 days before treatment. U373
parental cells were used for stable cell line generation. U373 cells were
transfected by nucleofection (Cell Line Nucleofector Kit V, program
T-020; Amaxa). Cells were maintained in DMEM supplemented with 10%
FCS and 1% penicillin-streptomycin solution (v/v). Cells stably transfected
with pcDNA3.1 TRIL were selected and cloned using 300 g/ml neomycin
analog G418 (InvivoGen) with or without 10 g/ml blasticidin. Overex-
pression of TRIL was confirmed by immunoblotting and/or FACS analysis.
Stable Chines hamster ovary (CHO) cells were generated using the
PCDNA5 vector from Invitrogen (V652020). Positive clones were selected
using hygromycin antibiotics.
RT-PCR
For quantitative real-time PCR, cDNA was transcribed using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Prim-
ers and probes for human and mouse TRIL were purchased from
Applied Biosystems (assay identifications Hs00274460_s1 and
Mm00503080_s1, respectively).
Small interfering RNA (siRNA)
To test the biological function of TRIL, we purchased a RNA interference
duplex (Qiagen). Oligonucleotide 1 sequence for human TRIL was
GGCUGGAUCUAGACGGCAA (sense strand sequence for human
TRIL). The additional oligonucleotide tested was CGUAGGAAACUGC
GGGCUAUU (Dharmacon). Sequence scrambled negative control oligo-
nucleotide for TRIL was CGUCACUGGGUGAGCAAGA. siRNAs were
tested at a number of concentrations. Following optimization, 50 nM of
siRNA oligonucleotide 1 (Qiagen) showed the most consistent knockdown
in all cell types. U373/CD14 cells were seeded at 5  105cells/ml in 6-well
plates. Oligonucleotides were transfected using Oligofectamine (Invitro-
gen) in serum-free medium. After 6 h, 1 ml of medium containing 20%
FCS and 2 L-glutamine was added to the cells. Cells were harvested after
48–72 h and used for further analysis. Human PBMC, THP1 cells, and
murine mixed glial cells were transfected with siRNA using an Amaxa
electroportator and a Cell Line Nucleofector Kit V, program V-01
(PBMC), S-019 (THP1), and T-020 (mixed glial cells), according to the
manufacturer’s instructions. One  106cells/ml PBMC or THP1 cells were
used per point for nucleofection. Cells were harvested after 72 h and used
for further analysis.
Immunoprecipitation, glycosidase treatment, and LPS- binding
assays
HEK293 cells were seeded at 2  105cells/ml in 10- cm dishes. Flag-TLR4
(pcDNA3.1) was transfected using Genejuice Transfection Reagent (No-
vagen). Cells were treated as outlined in the figure legends. Cells were
washed in ice-cold PBS and lysed in 500 l of high-stringency lysis buffer
(50 mM HEPES (pH 7.5), 100 mM NaCl, 1 mM EDTA, 10% glycerol, and
1% Nonidet P-40). Supernatants were removed and added to the relevant
precoupled Ab. Fifty microliters of each lysate was retained to confirm
expression of TRIL and TLR4. Samples were incubated overnight at 4°C.
Following incubation, the immune complexes were washed twice with 1 ml
of lysis buffer and once with ice-cold PBS. All supernatants were removed
and beads were resuspended in 30 l of 5 sample buffer. The samples
were boiled for 5 min and SDS-PAGE analysis was performed as described
previously.
TRIL was immunoprecipitated from TRIL-Flp-In CHO cells (1–2 
106 cells/point) using anti-TRIL-coupled protein A-Sepharose beads. The
complex was washed twice with high-stringency lysis buffer and once with
PBS before resuspending the beads in glycosidase reaction buffer. Beads
were incubated with 2.5 U of PNGase F (PP0261–1KT; Sigma-Aldrich) for
40 min at 37°C. SDS-PAGE sample buffer was added and the samples were
analyzed by Western blotting.
HEK293 cells were seeded at 2  105cells/ml in 10-cm dishes. Cells
were transfected with 4 g of pcDNA-TRIL plasmid. After 24 h, lysates
containing overexpressed TRIL were incubated with 2 g/ml biotinylated
LPS (InvivoGen) or 3 g/ml biotinylated CpG (MWG) before precipitation
on avidin beads (Pierce). The complexes were washed in high-stringency
buffer and analyzed by SDS-PAGE. LPS pull-down experiments were also
conducted in the presence and absence of nonbiotinylated LPS for 2 h at
room temperature before precipitation with avidin-agarose for a further 2 h.
Results
Identification and characterization of TRIL
A microarray was conducted on embryonic stem cells to identify
novel LPS-inducible genes. A previously uncharacterized gene
was identified, which we named TRIL (GenBank accession no.
NM_014817). The open reading frame of TRIL comprises 2436 bp
and is predicted to encode a protein of 811 aa with a calculated
molecular mass of 83 kDa. The chromosomal location has been
mapped to chromosome 7q15.1 and the coding region consists of
one exon. A number of LRR glycoproteins have evolved to encode
their entire LRR cassette within one exon such as synleurin (13),
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chondroadherin (14), and 5T4 oncofetal leucine-rich glycoprotein
(15) in addition to TLR1, TLR2, and TLRs 5–10. The TRIL pro-
tein sequence is highly conserved across species and is shown for
humans and mice in Fig. 1. Analysis of the TRIL sequence using
Meta Server 3D-Jury structural homology software identified two
distinct structured domains: an N-terminal LRR domain followed
by a type III fibronectin domain before the putative transmembrane
region (Fig. 2A). There was no predicted structural domain in the
proposed intracellular portion of TRIL. The N terminus of the
protein contains a 23-aa signal sequence as predicted by signal P,
suggesting that the protein is directed to the endoplasmic reticulum
and from there it could go to several types of vesicles or to the
plasma membrane (16). It has a predicted isoelectric point of 9.7,
which we have confirmed by two-dimensional electrophoresis
(data not shown).
A homology model of the TRIL LRR region was generated
using Modeler 9v3 (12) and has the characteristic curved solenoid
of other LRR domains as shown in Fig. 2B. This model is based on
LINGO-1 and is also the common structural element found in the
TLRs and CD14. Altogether there are 13 LRR motifs and N- and
C-terminal capping structures typical of an extracellular LRR.
Each separate TRIL LRR is 24 residues long except for LRR7
which contains two single residue insertions (Fig. 2C). The aspar-
agine ladder is strictly conserved throughout.
TRIL expression profiling
We conducted quantitative RT-PCR to assess the expression of
TRIL. Results indicate that TRIL is most highly expressed in mu-
rine brain, spinal cord, day 11 embryo, and lung (Fig. 3A). All
samples were normalized against GAPDH and expressed relative
to the lowest detectable sample. Results from a human cDNA
panel are consistent with the murine results and also indicate high
levels of TRIL in the brain, ovary, small intestine, and spleen (Fig.
3B). Since high expression levels were found in brain, we inves-
tigated this further and found that TRIL is highly expressed on rat
cortical astrocytes and on day 5 cerebellar granule neurons (Fig.
3C). Expression of TRIL was also observed throughout the brain
in the hippocampus, cortex, and cerebellum at the protein level and
also at the RNA level using laser capture microdissection (data not
shown).
FIGURE 1. Sequence analysis of TRIL. The amino acid sequence of
human and mouse TRIL. Regions with identical amino acids are high-
lighted in black.
FIGURE 2. The TRIL LRR domain. A, Schematic depicting the domain topology of TRIL. The extracellular region (residues 1–697) contains both a
LRR domain and type III fibronectin domain. The predicted transmembrane domain is shaded black. The intracellular section (residues 718–811; light gray)
is predicted to lack specific structured domains. B, Homology model of the TRIL LRR domain using the LINGO-1 ectodomain (pdb 2id5) as a template.
The LRR is shown as a cartoon representation inside the molecular surface. LRR1 is located at the top of the image and the insert containing LRR7
is highlighted in purple. C, Human TRIL LRR sequences. In the consensus sequence, L  leucine, isoleucine, valine, or phenylalanine; N 
asparagine, cysteine, serine, or threonine; F  phenylalanine or leucine. For each TRIL LRR consensus sequence, residues are in bold and deviations
from the consensus are highlighted. The high levels of deviation from the consensus in the latter half of LRR13 reflect the movement of the structure
into the C-terminal cap.
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TRIL is a LPS-inducible protein
Abs to TRIL were generated to measure endogenous protein lev-
els. The peptide sequence to which the Abs were raised is highly
conserved across a number of species. The specificity of the Ab
was confirmed by peptide competition as shown in Fig. 4A for both
overexpressed (lane 1 vs lane 3) and endogenous (lane 2 vs lane
4). As can be seen from this figure when TRIL is transiently over-
expressed in 293 cells, it migrates as a doublet. A number of pu-
tative N-linked glycosylation sites can be identified in the TRIL
sequence that may explain the different banding patterns observed
on electrophoresis. A faster migrating form of the protein was
indeed detected following treatment with glycosidase as shown in
Fig. 4B (middle lane), suggesting that the protein does undergo this
form of posttranslational modification. Although TRIL expression
occurs at basal levels in some cell types, we have also observed
enhanced expression of TRIL following treatment with LPS. Since
TRIL is highly expressed in the brain and particularly on astro-
cytes, initial studies were conducted in the U373 human astrocy-
toma cell line. Once again Ab specificity was confirmed using
peptide competition assays. We generated a U373 cell line stably
overexpressing TRIL. Similar to the HEK293 cells, overexpressed
TRIL migrates as a doublet and both this band and the band cor-
responding to endogenous TRIL were competed out in this exper-
iment (Fig. 4C). Wild-type U373 cells respond poorly to LPS in
the absence of CD14; therefore, we used a cell line stably express-
ing CD14 to confer increased LPS responsiveness when analyzing
TRIL expression. TRIL was expressed basally and induced by LPS
at 2 and 4 h (Fig. 4D). TRIL was also induced in murine bone
marrow- derived macrophages (BMDM) after 2 and 4 h and was
sustained at 24 h following treatment with LPS (Fig. 4E). In vivo
expression of TRIL was then assessed in C57BL/6 mice that were
exposed to i.p. injection of LPS for 3 h before sacrifice. TRIL is
clearly induced in the brain following LPS injection as shown in
Fig. 4F. LPS treatment also induced TRIL in primary human
PBMC and a marked induction over basal was seen at 60 and 120
min (Fig. 4G).
TRIL is a component of the TLR4 signaling complex
We next sought to determine whether TRIL plays any role in LPS
signaling given the nature of the extracellular domain and en-
hanced expression following LPS stimulation. As mentioned
above, wild-type U373 cells respond poorly to LPS in the absence
of CD14 although they express basal levels of both TLR4 and
MD2. We compared LPS-induced cytokine production in wild-
type cells compared with cells stably overexpressing TRIL. As can
be seen in Fig. 5, stable overexpression of TRIL markedly in-
creased the induction of IL-6, IL-8, and RANTES in response to
LPS (Fig. 5, A–C, respectively). Given this ability of TRIL to
markedly enhance LPS signaling, we next sought to address
whether TRIL can interact with components of the TLR4 receptor
complex. HEK293 cells were transfected with Flag-tagged TLR4
and stimulated with LPS for various times (Fig. 6A). TLR4 was
found to interact with endogenous TRIL (Fig. 6, lane 1) and the
FIGURE 3. Expression profile of TRIL. TaqMan quantitative RT-PCR
was conducted on a murine (A) and human (B) cDNA panel to assess TRIL
expression. TRIL mRNA levels were normalized against GAPDH and ex-
pressed relative to the lowest detectable sample. C, Cerebellar granule
neurons and cortical astrocytes were prepared from rat brain samples. TRIL
mRNA levels were normalized against GAPDH and expressed relative to
total brain. CG, Cerebellar granule.
FIGURE 4. TRIL is a LPS-inducible gene. A, HEK293 cells were trans-
fected with 3 g of TRIL (lanes 1 and 3) or mock transfected (lanes 2 and
4). Samples were either probed directly using anti-TRIL Ab or the primary
Ab was incubated at 30oC for 30 min with the corresponding competing
peptide (20 g/ml) before detection. B, TRIL was immunoprecipitated
from CHO cells stably overexpressing TRIL. The complex was resus-
pended in glycosidase reaction buffer before incubation with 2.5 U of
PNGase F. Samples were then probed using anti-TRIL Ab. C, Wild-type
(WT) U373 and U373 cells stably overexpressing TRIL were treated as
described in A. U373/CD14 cells (D) and BMDM (E) were stimulated with
100 ng/ml LPS for the indicated time points and expression of TRIL or
-actin was assessed by Western blot. F, C57BL/6 mice were injected i.p.
with LPS or water for 3 h. Brain extracts were immunoblotted for TRIL
and -actin expression. G, Human PBMC were stimulated with LPS for the
indicated time points. Protein lysates were immunoblotted for TRIL and
-actin expression as indicated.
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strength of this interaction was found to increase on LPS stimu-
lation, being optimal from 1 h (Fig. 6, lane 3).
Having established that TRIL was capable of interacting with
TLR4, we next investigated whether TRIL can bind LPS. HEK293
cells were transfected with full-length TRIL and lysates were in-
cubated with biotinylated LPS or biotinylated CpG as a control for
2 h before precipitation with avidin beads. As shown in Fig. 6B,
TRIL could clearly be detected following incubation with LPS;
however, no interaction was observed with CpG (Fig. 6B, top). We
also found that this interaction could be competed out using un-
labeled LPS (Fig. 6B, bottom). This standard assay strongly indi-
cates that TRIL can interact with components of the TLR4 receptor
complex and LPS itself.
Knockdown of TRIL affects LPS signaling
We next performed siRNA knockdown experiments to determine
whether TRIL functions in the TLR4 signaling pathway. TRIL
knockdown was confirmed at the protein level in U373/CD14 cells
(Fig. 7A, gel 1, lanes 4–6). This result also further confirms the
specificity of the TRIL Ab. Silencing of TRIL affected the LPS
signaling pathway by delaying the degradation of IB in re-
sponse to LPS (Fig. 7A, gel 2, lanes 4–6). This result was con-
firmed with an additional siRNA oligonucleotide. We also found
that TRIL knockdown inhibited LPS-induced phosphorylation of
p38 (Fig. 7A, gel 3, lanes 4–6). Transfection with a scrambled
version of the oligonucleotide (Fig. 7B, Neg. Ctl, gel 1, lanes 1–3)
did not affect endogenous levels of TRIL nor did it ablate LPS-
induced readouts. Importantly, silencing of TRIL did not affect the
TNF- signaling pathway and IB degradation occurred as nor-
mal in all samples in response to TNF- (Fig. 7B, gel 2, lanes
4–6). TRIL expression was also knocked down in the human
monocytic cell line THP1. This was confirmed at the protein level
(Fig. 7C, inset) and cytokine production was monitored. Silencing
of TRIL in these cells led to a decrease in IL-6 and TNF- pro-
duction following LPS stimulation (Fig. 7, C and D). To ensure
that there were no off-target affects, endogenous levels of TLR4
were tested and found to be unaffected by knockdown of TRIL
(data not shown).
We also knocked down TRIL expression in human PBMC. De-
livery of a FITC-tagged TRIL siRNA oligonucleotide was con-
firmed by FACS analysis and transfection efficiency as achieved
by Amaxa electroporation was found to be close to 100% (data not
shown). Knockdown was confirmed at the protein level (Fig. 8A,
inset). In agreement with results mentioned above, silencing of
TRIL affected LPS signaling by delaying IB degradation and
inhibiting the phosphorylation of p38 (data not shown). At the
FIGURE 5. TRIL modulates responses to LPS. A, U373 cell lines stably
expressing TRIL were generated. Cells were maintained in complete me-
dium before stimulation with the indicated concentration of LPS for 24 h.
IL-6 (A), IL-8 (B), and RANTES (C) levels were measured by ELISA.
Results are expressed as a mean  S.D for triplicate determinations. WT,
Wild type.
FIGURE 6. TRIL associates with TLR4 and binds LPS. A, HEK293
cells were transfected with 4 g of Flag-TLR4 for 24 h before stimulation
with 100 ng/ml LPS for the indicated time points. Interaction with endog-
enous TRIL was assessed following immunoprecipitation (IP; top gel) with
anti-Flag beads. TRIL and TLR4 expression levels were examined in cell
lysates (middle and bottom gels, respectively). B, HEK293 cells were trans-
fected with 4 g of TRIL for 24 h. Cell lysates were incubated with bio-
tinylated LPS or biotinylated CpG for 2 h before precipitation on avidin
beads (top gel). Lysates were assessed for TRIL expression (middle gel).
Cell lysates containing overexpressed TRIL were incubated with biotinyl-
ated LPS in the presence or absence of nonbiotinylated LPS (bottom gel)
for 2 h before precipitation on avidin beads. Lysates were analyzed by
SDS-PAGE and immunoblotted (IB) with anti-TRIL. Ctl, Control.
FIGURE 7. Knockdown of TRIL affects the LPS but not the TNF-
signaling pathway. A, U373/CD14 cells were transfected with an siRNA
oligonucleotide specific to TRIL (50 nM) or an equivalent concentration of
scrambled control (Neg. Ctl.) oligonucleotide. Each oligonucleotide was
transfected for 72 h before stimulation with LPS (100 ng/ml). Cells were
harvested and immunoblotted for TRIL, IB, phospho-p38 (pp38), and
-actin. B, Cells were stimulated with 20 ng/ml TNF- and immunoblotted
for TRIL, IB, and -actin. C and D, THP1 cells were transfected with
control and TRIL-specific oligonucleotides. Knockdown or control cells
were stimulated with LPS (100 ng/ml) for 24 h. IL-6 (C) and TNF- (D)
levels were measured by ELISA. Results are expressed as mean  SD for
triplicate determinations. , p  0.001. All results are representative of
three separate experiments. Neg. Ctl, Negative control.
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cytokine level, knockdown of TRIL led to a decrease in the
production of TNF- and IL-6 in response to LPS (Fig. 8, A and
B). We were unable to test the effect of knockdown of TRIL on the
production of cytokines by TNF as a control, as TNF could only
induce minimal responses in PBMC; however, knockdown of
TRIL did not affect CpG-induced IL-6 production (Fig. 8C). In-
terestingly, knockdown of TRIL also inhibited the induction of
TNF- by Pam3Cys4 as shown in Fig. 8D. Finally, we also looked
at an additional readout in murine mixed glial cells that produce
RANTES in response to LPS stimulation. Approximately 50%
knockdown was achieved as shown at the protein level in Fig. 8E
(inset). Silencing of TRIL in these cells led to a decrease in RAN-
TES production following LPS stimulation (Fig. 8E). Taken to-
gether, these results indicate that TRIL is a key part of the TLR4
complex and is important for LPS responses.
Discussion
TLR signaling in response to LPS requires a number of proteins
that function together as part of a complex to optimally induce
proinflammatory responses. We have identified a novel component
of this complex, which we have named TRIL. This protein con-
tains 13 LRRs, a fibronectin domain, and a putative transmem-
brane domain. The predicted domain organization of TRIL is con-
sistent with that of Dolan et al. (17) who grouped TRIL (referred
to as KIAA0644) with the TLRs following sequence analysis of a
number of LRR-containing proteins. Furthermore, the consensus
sequence of the TRIL LRRs broadly matches that of the TLR
family assigned by Matsushima et al. (18) comprising LxxLxLxx-
NxLxxLxxxxF/LxxLxx. Consistent with other LRR proteins,
TRIL can be modeled with the characteristic curved solenoid
shape, contains N- and C-terminal cysteine caps and a conserved
asparagine backbone.
We have found that TRIL is expressed at high levels in the brain
and particularly in astrocytes. Although the protein is expressed
basally, we have also found that levels of TRIL increase upon LPS
stimulation as shown for U373s, murine BMDM, and human
PBMC. TRIL was also induced by LPS in vivo in mouse brain
possibly by LPS penetrating the blood-brain barrier or via induc-
tion of cytokines such as IL-1. TRIL induction may therefore help
prolong LPS signaling. An immediate question that arises relates
to the role of TRIL in relation to CD14, given that both proteins
possess LRR domains and can bind LPS. Indeed, there is signifi-
cant structural similarity between the LRR regions of TRIL and
CD14; however, at the amino acid level, the sequence identity is
17%. In addition, both proteins can enhance responses to LPS
when stably expressed in U373 cells. TRIL may therefore be a
functional homolog of CD14. CD14 exists as a GPI-anchored pro-
tein and also as soluble factor which functions to transfer LPS to
the TLR4 receptor complex. Interestingly, we have observed a
soluble form of TRIL in FCS. This form was identified by mass
spectroscopic analysis; however, this is preliminary data and we
are currently investigating this further. One possibility is that TRIL
acts a substitute for CD14 in cells where the latter may be ex-
pressed at low levels. Alternatively, TRIL may be acting as part of
the LPS transfer mechanism that exists between accessory mole-
cules and TLR4. In our studies, LPS treatment of cells increased
the association of TRIL with TLR4. In addition, we observed that
TRIL could specifically associate with LPS. Additional experi-
ments will determine whether both TRIL and CD14 are required
for optimal TLR4 responses.
TRIL could also have a role similar to RP105, an LRR- con-
taining protein with no apparent signaling domain. RP105 binds to
MD1 to positively or negatively regulate TLR4 signaling in a cell-
type-dependent manner (3, 11). We are currently exploring
whether TRIL can bind to MD1 and/or MD2 as well as examining
the effects of TRIL in additional cell types.
A number of accessory proteins have also been shown to be
required for TLR2 signaling. CD14 and vitronectin facilitate the
transfer of lipopeptides to the TLR2 receptor complex (19, 20). It
therefore appears that multiple accessory proteins are required by
both TLR2 and TLR4 for optimum responses to lipid-based ago-
nists. We have preliminary data to suggest that TRIL could also be
involved in TLR2 signaling since knockdown of TRIL affected
Pam3Cys4-induced TNF- production. Further work will enable
us to determine whether TRIL influences additional TLR signaling
pathways.
The relatively high expression of TRIL in the brain and the in
vivo induction of TRIL by LPS in this tissue is also of interest. It
appears that inflammation following brain injury can have a pro-
tective or destructive role depending on which cytokines are pro-
duced (21, 22). TLR4-deficient mice have been examined follow-
ing experimentally induced stroke and were found to have lower
infarct volumes and lower expression of proteins associated with
brain damage such as IRF-1, NO synthase, cyclooxygenase 2, and
matrix metalloproteinase 9 (23, 24). TLR4 has also been shown to
mediate innate immunity to bacterial infection in the CNS along
with TLR2 (25). Furthermore, TLR4 has been shown to modulate
FIGURE 8. Knockdown of TRIL in primary cells affects LPS re-
sponses. A and B, PBMC were isolated and transfected with control (Ctl,
CTL) or TRIL-specific siRNA. Cells were stimulated with 100 ng/ml LPS
for 24 h before being harvested and immunoblotted for TRIL (inset). Su-
pernatants were analyzed for IL-6 (A) and TNF- (B) production. C,
PBMC were stimulated with 500 nM CpGB for 24 h. Supernatants were
analyzed for IL-6. Results are expressed as mean  SD for triplicate de-
terminations (, p  0.01 and , p  0.001) Similar results were ob-
tained in three additional experiments. D, PBMC were isolated and trans-
fected with control or TRIL-specific siRNA. Cells were stimulated with 1
g/ml Pam3Cys4 for 24 h before being harvested. Supernatants were an-
alyzed for TNF- production. Results are expressed as mean  SD for
triplicate determinations (, p  0.05). E, Mixed glial cells were isolated
from 1-day-old neonatal mice and cultured for 10 days. Cells were then
transfected with control or TRIL-specific siRNA and stimulated with 100
ng/ml LPS for 24 h before being harvested and immunoblotted for TRIL
(inset). Supernatants were analyzed for RANTES production. Neg Ctl,
Negative control.
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hippocampal neurogenesis with TLR4-defective mice showing en-
hanced neuronal proliferation and differentiation (26). TRIL may
participate with TLR4 in these various responses. Given their
structural similarity, there may also be a relationship between
TRIL and the NOGO and LINGO family of proteins, which similar
to TLR8 are inhibitors of neurite outgrowth (27, 28). Neuroinflam-
mation has also been associated with neurodegenerative diseases
such as Alzheimer’s disease (29, 30). Interestingly, we have pre-
liminary data which suggest that TRIL expression is increased in
the brains of patients with Alzheimer’s disease. Further studies
will need to be conducted to determine whether TRIL plays a role
in the pathogenesis of this condition.
In conclusion, we have identified a novel component of the
TLR4 receptor complex which could represent a new therapeutic
target to limit dysregulated TLR4 signaling and may have partic-
ular relevance in the context of neuroinflammation.
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